Greg M Delgoffe
Overview
Explore the profile of Greg M Delgoffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
8107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buj R, Cole A, Danielson J, Xu J, Hurd D, Kishore A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975044
Approximately 50% of cancers exhibit decreased expression ( ), which is linked to immune checkpoint blockade (ICB) resistance. While is traditionally recognized as a tumor suppressor and cell cycle regulator,...
2.
Frisch A, Wang Y, Xie B, Yang A, Ford B, Joshi S, et al.
Cell Metab
. 2025 Jan;
PMID: 39879981
Cellular therapies are living drugs whose efficacy depends on persistence and survival. Expansion of therapeutic T cells employs hypermetabolic culture conditions to promote T cell expansion. We show that typical...
3.
Peralta R, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, et al.
Nat Immunol
. 2024 Nov;
25(12):2297-2307.
PMID: 39516648
CD8 T cells are critical mediators of antitumor immunity but differentiate into a dysfunctional state, known as T cell exhaustion, after persistent T cell receptor stimulation in the tumor microenvironment...
4.
Nieves-Rosado H, Banerjee H, Gocher-Demske A, Manandhar P, Mehta I, Ezenwa O, et al.
J Immunol
. 2024 Sep;
213(10):1488-1498.
PMID: 39345172
Expression of T cell Ig and mucin domain-containing protein 3 (Tim-3) is upregulated on regulatory T cells (Tregs) during chronic viral infections. In several murine and human chronic infections, the...
5.
DePeaux K, Gunn W, Rivadeneira D, Delgoffe G
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39153823
Background: Oncolytic viruses (OVs) are an attractive way to increase immune infiltration into an otherwise cold tumor. While OVs are engineered to selectively infect tumor cells, there is evidence that...
6.
Andrews L, Butler S, Cui J, Cillo A, Cardello C, Liu C, et al.
Cell
. 2024 Aug;
187(16):4355-4372.e22.
PMID: 39121848
Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in...
7.
Zandberg D, Zenkin S, Ak M, Mamindla P, Peddagangireddy V, Hsieh R, et al.
Head Neck
. 2024 Jul;
47(1):129-138.
PMID: 39080968
Background: We retrospectively evaluated radiomics as a predictor of the tumor microenvironment (TME) and efficacy with anti-PD-1 mAb (IO) in R/M HNSCC. Methods: Radiomic feature extraction was performed on pre-treatment...
8.
Shao L, Srivastava R, Delgoffe G, Thorne S, Sarkar S
Cancer Immunol Res
. 2024 Mar;
12(6):779-790.
PMID: 38517470
IFN regulatory factor 1 (IRF1) can promote antitumor immunity. However, we have shown previously that in the tumor cell, IRF1 can promote tumor growth, and IRF1-deficient tumor cells exhibit severely...
9.
Wilfahrt D, Delgoffe G
Nat Immunol
. 2024 Jan;
25(2):206-217.
PMID: 38238609
This Review explores the interplay between T cell activation and cell metabolism and highlights how metabolites serve two pivotal functions in shaping the immune response. Traditionally, T cell activation has...
10.
Kumar A, Delgoffe G
Cell Metab
. 2023 Dec;
35(12):2101-2103.
PMID: 38056428
The malate shuttle is known to maintain the balance of NAD/NADH between the cytosol and mitochondria. However, in T cells, it primarily detoxifies ammonia (via GOT1-mediated production of 2-KG in...